By 1997, Ng and colleagues had identified the C-terminal segment of human GH as the primary region governing fat metabolism, and created AOD 9604 by adding a tyrosine residue to the fragment to enhance its stability
This mechanism raises the critical discontinuation question - does stopping GHK-Cu immediately halt enhanced collagen production returning synthesis rates to pre-treatment baseline, or does the improved dermal environment created during treatment continue supporting elevated collagen production through positive feedback mechanisms where better matrix structure itself promotes ongoing synthesis even without continuous peptide stimulation
Some compounding pharmacies and research protocols use slightly different increments, such as 0.25, 0.50, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, and 2.4mg
Reported ranges from research/community examples, not recommendations
Effective for weakened animals after the event